Q2 2024

Filed Aug 9, 2024 · 10-Q · 40 days after period end · 0001615219-24-000071

Q2 2024 · 10-Q

Revenue—

Net Income

-$1.42M

N/M vs Q2 2023

EPS Diluted

-$2.37

N/M vs Q2 2023

Operating Income-$1,467,517N/M

Operating Cash Flowderived-$1,072,192N/M

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	—	—	$0.00	$571.39K
Net Income	-$1.42M	-$3.88M	-$4.72M	-$3.07M
EPS Diluted	-$2.37	-$11.45	-$2.20	-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR